<HTML>
<HEAD>
<TITLE>Form S-8</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>As filed with the Securities and Exchange Commission on May&nbsp;6, 2010</B>
</DIV>


<DIV align="right" style="font-size: 10pt; margin-top: 10pt">Registration
No.&nbsp;333-____
</DIV>


<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>




<DIV align="center" style="font-size: 14pt; margin-top: 10pt"><B>SECURITIES AND EXCHANGE COMMISSION</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B>Washington, D.C. 20549</B>
</DIV>

<DIV align="center" style="font-size: 18pt; margin-top: 10pt"><B>FORM S-8</B>
</DIV>


<DIV align="center" style="font-size: 12pt; margin-top: 10pt"><B>REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933</B>
</DIV>

<DIV align="center" style="font-size: 24pt; margin-top: 10pt"><B>TRINITY BIOTECH PLC</B>
</DIV>

<DIV align="center" style="font-size: 10pt">(Exact name of Registrant as specified in its charter)</DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="47%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>Republic of Ireland</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>Not Applicable</B></TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">(State or other jurisdiction of
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(I.R.S. Employer</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">incorporation or organization)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Identification No.)</TD>
</TR>
<!-- End Table Body --></TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>IDA Business Park<BR>
Bray, Co. Wicklow<BR>
Ireland<BR>
011 353 1 276 9800</B><BR>
(Address of Registrant&#146;s principal executive offices)</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>TRINITY BIOTECH PLC EMPLOYEE SHARE OPTION PLAN 2006</B><BR>
(full title of the plan)</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>Alan J. Bernstein, Esq.<BR>
Carter Ledyard &#038; Milburn LLP<BR>
2 Wall Street<BR>
New York, NY 10005<BR>
(212)&nbsp;732-3200</B><BR>
(Name and address of agent for service)<BR>
(Telephone number, including area code, of agent for service)</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>Copies to:</B></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>Alan J. Bernstein, Esq.<BR>
Carter Ledyard &#038; Milburn LLP<BR>
2 Wall Street<BR>
New York, NY 10005<BR>
(212)&nbsp;732-3200</B></DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
non-accelerated filer, or a smaller reporting company. See the definitions of &#147;large accelerated
filer,&#148; &#147;accelerated filer&#148; and &#147;smaller reporting company&#148; in Rule&nbsp;12b-2 of the Exchange Act.
(Check one):
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="22%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="22%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="22%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="22%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top">Large accelerated filer <FONT face="Wingdings">&#111;</FONT>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Accelerated filer <FONT face="Wingdings">&#254;</FONT>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Non-accelerated filer <FONT face="Wingdings">&#111;</FONT>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><FONT style="white-space: nowrap">Smaller reporting company <FONT face="Wingdings">&#111;</FONT></FONT></TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><FONT style="white-space: nowrap">(Do not check if a smaller reporting company)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body --></TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>CALCULATION OF REGISTRATION FEE</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="1%">&nbsp;</TD>
    <TD width="46%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD><!-- VRule -->
    <TD width="1%">&nbsp;</TD>
    <TD width="11%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD><!-- VRule -->
    <TD width="1%">&nbsp;</TD>
    <TD width="11%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD><!-- VRule -->
    <TD width="1%">&nbsp;</TD>
    <TD width="11%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD><!-- VRule -->
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>

    <TD width="1%">&nbsp;</TD>
</TR><TR style="font-size: 1px" valign="bottom">
    <TD nowrap align="left" colspan="17" style="border-bottom: 3px double #000000">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">    <TD width="1%">&nbsp;</TD>

    <TD>&nbsp;</TD>
    <TD style="border-right: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD style="border-right: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Proposed</TD>
    <TD style="border-right: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Proposed</TD>
    <TD style="border-right: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">    <TD width="1%">&nbsp;</TD>

    <TD>&nbsp;</TD>
    <TD style="border-right: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD style="border-right: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">maximum</TD>
    <TD style="border-right: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">maximum</TD>
    <TD style="border-right: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">    <TD width="1%">&nbsp;</TD>

    <TD>&nbsp;</TD>
    <TD style="border-right: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Amount to be</TD>
    <TD style="border-right: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">offering price</TD>
    <TD style="border-right: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">aggregate</TD>
    <TD style="border-right: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Amount of</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">    <TD width="1%">&nbsp;</TD>

    <TD nowrap align="left">Title of securities to be registered</TD>
    <TD style="border-right: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">registered</TD>
    <TD style="border-right: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">per share</TD>
    <TD style="border-right: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">offering price</TD>
    <TD style="border-right: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">registration fee</TD>
    <TD width="1%">&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD width="1%" style="border-top: 1px solid #000000">&nbsp;</TD>

<TD valign="top" style="border-top: 1px solid #000000"><DIV style="margin-left:15px; text-indent:-15px">Class&nbsp;A Ordinary
Shares represented
by American
Depository Shares
(1)
</DIV></TD>
    <TD style="border-right: 1px solid #000000; border-top: 1px solid #000000">&nbsp;</TD>
    <TD style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD align="right" valign="bottom" style="border-top: 1px solid #000000">5,000,000 (2)
</TD>
    <TD style="border-right: 1px solid #000000; border-top: 1px solid #000000">&nbsp;</TD>
    <TD style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD align="right" valign="bottom" style="border-top: 1px solid #000000">$5.98 (3)
</TD>
    <TD style="border-right: 1px solid #000000; border-top: 1px solid #000000">&nbsp;</TD>
    <TD style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD align="right" valign="bottom" style="border-top: 1px solid #000000" nowrap>$29,900,000 (3)
</TD>
    <TD style="border-right: 1px solid #000000; border-top: 1px solid #000000">&nbsp;</TD>
    <TD style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD nowrap align="right" valign="bottom" style="border-top: 1px solid #000000">$</TD>
    <TD align="right" valign="bottom" style="border-top: 1px solid #000000">2,131.87</TD>
    <TD nowrap valign="bottom" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD width="1%" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR style="font-size: 1px" valign="bottom">
    <TD nowrap align="left" colspan="17" style="border-top: 3px double #000000">&nbsp;</TD>
</TR>

<!-- End Table Body --></TABLE>
</DIV>




<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR style="font-size: 6pt">
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="96">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD nowrap align="left">(1)</TD>
    <TD>&nbsp;</TD>
    <TD>American Depositary Shares (&#147;ADS&#148;), each ADS representing four Class&nbsp;A Ordinary Shares,
nominal value US$0.0109 per share (&#147;Common Stock&#148;) of Trinity Biotech plc (the &#147;Company&#148;),
have been registered on a separate Registration Statement on Form F-6.</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left">(2)</TD>
    <TD>&nbsp;</TD>
    <TD>The 5,000,000 Class&nbsp;A Ordinary Shares represent the number of shares issuable under the
Employee Share Option Plan 2006 (the &#147;Plan&#148;).</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left">(3)</TD>
    <TD>&nbsp;</TD>
    <TD>Calculated pursuant to Rule 457(c) under the Securities Act of 1933, on the basis of the
average of the high and low prices ($6.19 and $5.77) of an ADR, as quoted on the NASDAQ
Capital Market on May&nbsp;5, 2010.</TD>
</TR>

</TABLE>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">This Registration Statement shall become effective immediately upon filing as provided in Rule
462(a) under the Securities Act of 1933.
</DIV>

<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>





<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">







<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>PART I<BR>
INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Item&nbsp;1. Plan Information*</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Item&nbsp;2. Registrant Information and Employee Plan Annual Information*</B>
</DIV>




<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR style="font-size: 6pt">
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="96">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD nowrap align="left">*</TD>
    <TD>&nbsp;</TD>
    <TD>This information is not required to be included in, and is not incorporated by reference in, this
Registration Statement.</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">





<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>REOFFER PROSPECTUS</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>573,334 CLASS &#145;A&#146; ORDINARY SHARES<BR>
(143,333 ADS Equivalent)</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>TRINITY BIOTECH PLC</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>CLASS &#145;A&#146; ORDINARY SHARES</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>REPRESENTED BY AMERICAN DEPOSITARY SHARES</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">This prospectus is being used for the offering and sale from time to time by the selling
shareholders identified on page 8 of this prospectus of up to a maximum of 573,334 Class &#145;A&#146;
Ordinary Shares (four Class &#145;A&#146; Ordinary Shares represented by one American Depository Share
(&#147;ADS&#148;)) that have been issued under stock options previously granted under our 2006 Employee Stock
Option Plan (the &#147;Plan&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The selling shareholders, or their pledgees, donees, transferees or other
successors-in-interest, may offer the shares through public or private transactions, at prevailing
market prices or at privately negotiated prices. The selling shareholders will receive all of the
net proceeds from the sale of the shares. We will not receive any proceeds from the sale of the
shares. All costs, expenses and fees in connection with the registration of the shares offered
hereby will be borne by us. Brokerage commissions and similar selling expenses, if any,
attributable to the sale of shares will be borne by the selling shareholders.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Our ADSs are listed on the Nasdaq National Cap Market under the symbol &#147;TRIB.&#148; On May&nbsp;5, 2010,
the last sale price of our ADSs as reported by the Nasdaq National Cap Market was $5.94 per share.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"><B><I>Investing in our shares involves significant risks. You should read the &#147;Risk Factors&#148; section
beginning on page 1 of this prospectus before investing.</I></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%"><B><I>Neither the U.S. Securities and Exchange Commission nor any state securities commission has
approved or disapproved of these securities or determined if this prospectus is truthful or
complete. Any representation to the contrary is a criminal offense.</I></B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>The date of this Prospectus is May&nbsp;6, 2010</B>
</DIV>


<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">


<DIV align="left">
<!-- TOC -->
</DIV>
<DIV align="left">
<A name="tocpage"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>TABLE OF CONTENTS</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="77%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#101">SUMMARY</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#102">RISK FACTORS</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#103">NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#104">USE OF PROCEEDS</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">7</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#105">SELLING SHAREHOLDERS</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">7</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#106">PLAN OF DISTRIBUTION</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#107">LIMITATION OF LIABILITY AND INDEMNIFICATION MATTERS</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">11</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#108">LEGAL MATTERS</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">12</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#109">EXPERTS</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">12</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#110">WHERE YOU CAN FIND MORE INFORMATION</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">12</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#111">INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">13</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="c00479exv5.htm">Exhibit 5</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="c00479exv23w1.htm">Exhibit 23.1</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="c00479exv23w2.htm">Exhibit 23.2</A></FONT></TD></TR>
<!-- End Table Body --></TABLE>
</DIV>

<DIV align="left">
<!-- /TOC -->
</DIV>


<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->i<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">


<DIV align="left">
<A name="101"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>SUMMARY</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">You should rely only on the information contained in this prospectus or incorporated by
reference into this prospectus. We have not authorized any other person to provide you with
different information. The information contained in this prospectus is accurate only as of the date
of this prospectus, regardless of the time of delivery of this prospectus or of any sale of shares.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">This prospectus does not constitute an offer to sell, or a solicitation of an offer to buy,
nor shall there be any sale of these shares by any person in any jurisdiction in which it is
unlawful for that person to make such an offer, solicitation or sale.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Whenever we refer to &#147;Trinity Biotech&#148; or to &#147;us,&#148; or use the terms &#147;we&#148; or &#147;our&#148; in this
prospectus, we are referring to Trinity Biotech plc an Irish public limited company, and its
consolidated subsidiaries. To understand this offering fully, you should read this entire document
carefully, including particularly the &#147;Risk Factors&#148; section, as well as the documents identified
in the section titled &#147;Where you Can Find More Information.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><U><B>About Trinity Biotech</B></U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Trinity Biotech plc, an Irish public limited company, was formed in January&nbsp;1992 to acquire,
develop, manufacture and market rapid and laboratory based diagnostic tests for the detection of
various infectious diseases, blood coagulation disorders and other medical conditions. In addition,
we manufacture, acquire and market diagnostic tests and antibodies through our Irish, UK and German
subsidiaries as well as our U.S. subsidiaries, Clark Laboratories Inc. (trading as Trinity Biotech
(USA)&nbsp;Corp.), MarDx Diagnostics Inc., Biopool U.S., Inc., Primus Corporation and Fitzgerald
Industries International, Inc. Our address is IDA Business Park, Bray, Co. Wicklow, Ireland,
telephone number &#043;353 1 276 9800.
</DIV>
<DIV align="left">
<A name="102"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>RISK FACTORS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">You should carefully consider the risk factors listed below. These risk factors may cause our
future earnings or our financial condition to be less favorable than we expect. This list includes
only the risk factors that we believe are most important and is not a complete list of risks. Other
risks may be significant, and the risks listed below may affect us to a greater extent than
indicated. You should read this section together with the other information in this prospectus and
the documents that are incorporated into this prospectus be reference.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Trinity Biotech&#146;s operating results may be subject to fluctuations.</I></B>
</DIV>


<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Trinity Biotech&#146;s operating results may fluctuate as a result of many factors related to
its business, including the competitive conditions in the industry, major reorganisations of
the group&#146;s activities, loss of significant customers, delays in the development of new
products and currency fluctuations, as described in more detail below, and general factors
such as the size and timing of orders, the prevalence of various diseases and general economic
conditions. In the event of lower operating profits, this could have a negative impact on cash
generated from operations and also negatively impact shareholder value.</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV style="margin-top: 10pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>A need for capital might arise in the future if Trinity Biotech&#146;s capital requirements increase or
revenues decrease.</I></B>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Up to now Trinity Biotech has funded its operations through the sale of its shares and
securities convertible into shares, cash flows from operations and bank borrowings. Trinity
Biotech expects that the proceeds of equity financings, bank borrowings, lease financing,
current working capital and sales revenues will fund its existing operations and payment
obligations. However, if our capital requirements are greater than expected, or if our
revenues do not generate sufficient cashflows to fund our operations, we may need to find
additional financing which may not be available on attractive terms or at all. Any future
financing could have an adverse effect on our current shareholders or the price of our shares
in general.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Trinity Biotech&#146;s acquisition strategy may be less successful than expected, and therefore, growth
may be limited.</I></B>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Trinity Biotech has historically grown organically and through the acquisition of, and
investment in, other companies, product lines and technologies. There can be no guarantees
that recent or future acquisitions can be successfully assimilated or that projected growth in
revenues or synergies in operating costs can be achieved. Our ability to integrate future
acquisitions may also be adversely affected by inexperience in dealing with new technologies,
and changes in regulatory or competitive environments. Additionally, even during a successful
integration, the investment of management&#146;s time and resources in the new enterprise may be
detrimental to the consolidation and growth of our existing business.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>The diagnostics industry is highly competitive, and Trinity Biotech&#146;s research and development
could be rendered obsolete by technological advances of competitors.</I></B>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Trinity Biotech&#146;s principal business is the supply of medical diagnostic test kits and
related diagnostic instrumentation. The diagnostics industry is extremely competitive. Trinity
Biotech is competing directly with companies which have greater capital resources and larger
marketing and business organisations than Trinity Biotech. Trinity Biotech&#146;s ability to grow
revenue and earnings may be adversely impacted by competitive product and pricing pressures
and by its inability to gain or retain market share as a result of the action of competitors.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>We have invested in research and development (&#147;R&#038;D&#148;) but there can be no guarantees that
our R&#038;D programmes will not be rendered technologically obsolete or financially non-viable by
the technological advances of our competitors, which would also adversely affect our existing
product lines and inventory. The main competitors of Trinity Biotech (and their principal
products with which Trinity Biotech competes) include Siemens (Sysmex<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> CA, D-Dimer plus,
Enzygnost<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>), Inverness Medical Innovations, Inc. (Determine&#153; , Wampole&#153;, Athena&#153;), Diasorin
Inc. (Liasion&#153;, ETI&#153;), Abbott Diagnostics (AxSYM&#153;, IMx&#153;), Diagnostic Products Corp. &#151; DPC
(Immulite&#153;), Bio-Rad (ELISA, WB Bioplex&#153; &#038; A1c), Roche Diagnostics (COBAS AMPLICOR&#153;,
Ampliscreen&#153;, Accutrend&#153;) and OraSure Technologies, Inc (OraQuick<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>).</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV style="margin-top: 10pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Trinity Biotech is highly dependent on suitable distributors worldwide.</I></B>
</DIV>


<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Trinity Biotech currently distributes its product portfolio through distributors in
approximately 75 countries worldwide. Our continuing economic success and financial security
is dependent on our ability to secure effective channels of distribution on favourable trading
terms with suitable distributors.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Trinity Biotech&#146;s business could be adversely affected by changing market conditions resulting in
the reduction of the number of institutional customers.</I></B>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The diagnostics industry is in transition with a number of changes that affect the market
for diagnostic test products. Changes in the healthcare industry delivery system have resulted
in major consolidation among reference laboratories and in the formation of multi-hospital
alliances, reducing the number of institutional customers for diagnostic test products. There
can be no assurance that we will be able to enter into and/or sustain contractual or other
marketing or distribution arrangements on a satisfactory commercial basis with these
institutional customers.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Trinity Biotech&#146;s long-term success depends on its ability to develop new products subject to
stringent regulatory control. Even if new products are successfully developed, Trinity Biotech&#146;s
proprietary know-how, manufacturing techniques and trade secrets may be copied by competitors.
Furthermore, Trinity Biotech&#146;s patents have a limited life time and are thereafter subject to
competition with generic products. Also, competitors might claim an exclusive patent for products
Trinity Biotech plans to develop.</I></B>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>We are committed to significant expenditure on R&#038;D. However, there is no certainty that
this investment in research and development will yield technically feasible or commercially
viable products. Our organic growth and long-term success is dependent on our ability to
develop and market new products but this work is subject to very stringent regulatory control
and very significant costs in research, development and marketing. Failure to introduce new
products could significantly slow our growth and adversely affect our market share.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Even when products are successfully developed and marketed, Trinity Biotech&#146;s ownership of
the technology behind these products has a finite life. In general, generic competition, which
can arise through replication of the Trinity Biotech&#146;s proprietary know-how, manufacturing
techniques and trade secrets or after the expiration of a patent, can have a detrimental
effect on a product&#146;s revenue, profitability and market share. There can be no guarantee that
the net income and financial position of Trinity Biotech will not be adversely affected by
competition from generic products. Conversely, on occasion, certain companies have claimed
exclusive patent, copyright and other intellectual property rights to technologies in the
diagnostics industry. If these technologies relate to Trinity Biotech&#146;s planned products,
Trinity Biotech would be obliged to seek licences to use this technology and, in the event of
being unable to obtain such licences or it being obtainable on grounds that would be
materially disadvantageous to Trinity Biotech, we would be precluded from marketing such
products, which could adversely impact our revenues, sales and financial position.</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV style="margin-top: 10pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Trinity Biotech&#146;s patent applications could be rejected or the existing patents could be
challenged; our technologies could be subject to patent infringement claims; and trade secrets and
confidential know-how could be obtained by competitors.</I></B>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>We can provide no assurance that the patents Trinity Biotech may apply for will be obtained
or that existing patents will not be challenged. The patents owned by Trinity Biotech and its
subsidiaries may be challenged by third parties through litigation and could adversely affect
the value of our patents. We can provide no assurance that our patents will continue to be
commercially valuable.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Trinity Biotech currently owns 15 US patents with remaining patent lives varying from less
than one year to 13&nbsp;years. In addition to these US patents, Trinity Biotech owns a total of 8
additional non-US patents with expiration dates varying between the years 2010 and 2023.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Also, our technologies could be subject to claims of infringement of patents or proprietary
technology owned by others. The cost of enforcing our patent and technology rights against
infringers or defending our patents and technologies against infringement charges by others
may be high and could adversely affect our business.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Trade secrets and confidential know-how are important to our scientific and commercial
success. Although we seek to protect our proprietary information through confidentiality
agreements and other contracts, we can provide no assurance that others will not independently
develop the same or similar information or gain access to our proprietary information.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Trinity Biotech&#146;s business is heavily regulated and non-compliance with applicable regulations
could reduce revenues and profitability.</I></B>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Our manufacturing and marketing of diagnostic test kits are subject to government
regulation in the United States of America by the Food and Drug Administration (&#147;FDA&#148;), and by
comparable regulatory authorities in other jurisdictions. The approval process for our
products, while variable across countries, is generally lengthy, time consuming, detailed and
expensive. Our continued success is dependent on our ability to develop and market new
products, some of which are currently awaiting approval from these regulatory authorities.
There is no certainty that such approval will be granted or, even once granted, will not be
revoked during the continuing review and monitoring process.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>We are required to comply with extensive post market regulatory requirements.
Non-compliance with applicable regulatory requirements of the FDA or comparable foreign
regulatory bodies can result in enforcement action which may include recalling products,
ceasing product marketing, paying significant fines and penalties, and similar actions that
could limit product sales, delay product shipment, and adversely affect profitability.</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->4<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV style="margin-top: 10pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Trinity Biotech&#146;s success is dependent on certain key management personnel.</I></B>
</DIV>


<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Trinity Biotech&#146;s success is dependent on certain key management personnel. Our key
employees at December&nbsp;31, 2009 were Ronan O&#146;Caoimh, our CEO and Chairman, Rory Nealon, our
COO, and Kevin Tansley, our CFO and Company Secretary. Competition for qualified employees
among biotechnology companies is intense, and the loss of such personnel or the inability to
attract and retain the additional highly skilled employees required for the expansion of our
activities, could adversely affect our business. In the USA, the UK, France and Germany we
have been able to attract and retain qualified personnel. In Ireland, we have experienced some
difficulties in attracting and retaining staff due to competition from other employers in our
industry.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Trinity Biotech is dependent on its suppliers for the primary raw materials required for its test
kits.</I></B>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The primary raw materials required for Trinity Biotech&#146;s test kits consist of antibodies,
antigens or other reagents, glass fibre and packaging materials which are acquired from third
parties. Although Trinity Biotech does not expect to be dependent upon any one source for
these raw materials, alternative sources of antibodies with the characteristics and quality
desired by Trinity Biotech may not be available. Such unavailability could affect the quality
of our products and our ability to meet orders for specific products.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Trinity Biotech may be subject to liability resulting from its products or services.</I></B>
</DIV>


<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Trinity Biotech may be subject to claims for personal injuries or other damages resulting
from its products or services. Trinity Biotech has global product liability insurance in place
for its manufacturing subsidiaries up to a maximum of <FONT face="'Times New Roman',times,serif">&#128;</FONT>6,500,000 (about US$9,555,000) for any
one accident, limited to a maximum of <FONT face="'Times New Roman',times,serif">&#128;</FONT>6,500,000 (about US$9,555,000) in any one year period
of insurance. A deductible of US$25,000 is applicable to each insurance event that may arise.
There can be no assurance that our product liability insurance is sufficient to protect us
against liability that could have a material adverse effect on our business.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Currency fluctuations may adversely affect our earnings and assets.</I></B>
</DIV>


<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Trinity Biotech records its transactions primarily in US Dollars and Euro and prepares its
financial statements in US Dollars. A substantial portion of our expenses are denominated in
Euro. However, Trinity Biotech&#146;s revenues are primarily denominated in US Dollars. As a
result, the Group is affected by fluctuations in currency exchange rates, especially the
exchange rate between the US dollar and the Euro, which may adversely affect our earnings and
assets. The percentage of 2009 consolidated revenue denominated in US Dollars was
approximately 72%. Of the remaining 28% revenue, 22% relates to revenue denominated in Euro
and 6% relates to sterling and yen denominated revenues. Thus, a 10% decrease in the value of
the Euro would have approximately a 2% adverse impact on consolidated revenues.</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->5<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV style="margin-top: 10pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>As part of the process of mitigating foreign exchange risk, the principal exchange risk
identified by Trinity Biotech is with respect to fluctuations in the Euro. This is
attributable to the level of Euro denominated expenses exceeding the level of Euro denominated
revenues thus creating a Euro deficit. Trinity Biotech continuously monitors its exposure to
foreign currency movements and based on expectations on future exchange rate exposure
implements a hedging policy which may include covering a portion of this exposure through the
use of forward contracts. In the medium term, our objective is to increase the level of non-US
Dollar denominated revenue, thus creating a natural hedge of the non-US Dollar expenditure.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>The conversion of our outstanding employee share options and warrants would dilute the ownership
interest of existing shareholders.</I></B>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The warrants issued in 2008 and the total share options exercisable at April&nbsp;30, 2010 are
convertible into ADSs, 1 ADS representing 4 Class &#145;A&#146; Ordinary Shares. The exercise of the
share options exercisable and of the warrants will likely occur only when the conversion price
is below the trading price of our ADSs and will dilute the ownership interests of existing
shareholders. For instance, should the options and warrant holders of the 6,408,742 Class &#145;A&#146;
Ordinary Shares (1,602,185 ADSs) exercisable at April&nbsp;30, 2010 be exercised, Trinity Biotech
would have to issue 6,408,742 additional Class &#145;A&#146; Ordinary Share<I>s </I>(1,602,185 ADSs<I>)</I>. On the
basis of 83,016,585 Class &#145;A&#146; Ordinary Shares outstanding at April&nbsp;30, 2010, this would
effectively dilute the ownership interest of the existing shareholders by approximately 7%.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>It could be difficult for US holders of ADSs to enforce any securities laws claims against Trinity
Biotech, its officers or directors in Irish Courts.</I></B>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>At present, no treaty exists between the United States and Ireland for the reciprocal
enforcement of foreign judgements. The laws of Ireland do however, as a general rule, provide
that the judgements of the courts of the United States have in Ireland the same validity as if
rendered by Irish Courts. Certain important requirements must be satisfied before the Irish
Courts will recognize the United States judgement. The originating court must have been a
court of competent jurisdiction, the judgement may not be recognized if it is based on public
policy, was obtained by fraud or its recognition would be contrary to Irish public policy. Any
judgement obtained in contravention of the rules of natural justice will not be enforced in
Ireland.</TD>
</TR>

</TABLE>
</DIV>
<DIV align="left">
<A name="103"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>NOTE REGARDING FORWARD-LOOKING STATEMENTS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">This prospectus (including documents incorporated in it by reference in this prospectus)
contain forward-looking statements which involve known and unknown risks and uncertainties. We
include this notice for the express purpose of permitting Trinity Biotech to avail itself of the
protections of the safe harbor provided by the Private Securities Litigation Reform Act of 1995 for
all such forward looking statements. Examples of forward-looking statements include: (1)
projections of capital expenditures, revenues, growth, prospects, financial resources and other
financial matters; (2)&nbsp;statements of our plans or objectives; and (3)&nbsp;statements using the words
&#147;anticipate,&#148; &#147;believe,&#148; &#147;estimate,&#148; &#147;expect,&#148; &#147;may,&#148; &#147;intent,&#148; &#147;plan,&#148; &#147;project,&#148;
&#147;understand,&#148; and other verbs suggesting uncertainty.
</DIV>
<P align="center" style="font-size: 10pt; text-indent: 4%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->6<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Our ability to predict results of Trinity Biotech&#146;s operations or the effects of certain
events on Trinity Biotech&#146;s operating results is inherently uncertain. Therefore, we caution you to
consider carefully the matters described under the caption &#147;Risk Factors&#148; and certain other matters
discussed in this prospectus (including the documents incorporated by reference in this
prospectus), and other publicly available sources. Such risks and many other factors beyond the
control of Trinity Biotech&#146;s management could cause the actual results, performance or achievements
of Trinity Biotech to be materially different from any future results, performance or achievements
that may be expressed or implied by the forward-looking statements.
</DIV>
<DIV align="left">
<A name="104"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>USE OF PROCEEDS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The proceeds from the sale of the securities offered pursuant to this prospectus are solely
for the account of the selling shareholders. We will not receive any of the proceeds from any sale
of securities by the selling shareholders.
</DIV>
<DIV align="left">
<A name="105"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>SELLING SHAREHOLDERS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The following table sets forth, for the selling shareholders as of April&nbsp;30, 2010, the number
of Class &#145;A&#146; Ordinary Shares and Class &#145;B&#146; Ordinary Shares beneficially owned by each selling
shareholder, and the number of shares that may be offered by each selling shareholder using this
prospectus and each shareholder&#146;s percentage ownership of our outstanding shares assuming the sale
of all of the shares offered hereby. We prepared this table based on the information supplied to us
by the selling shareholders. Beneficial ownership is calculated based upon requirements of the
Securities and Exchange Commission and is not necessarily indicative of beneficial ownership for
any other purpose. Generally, the table is based on 83,016,585 Class &#145;A&#146; Ordinary Shares and
700,000 Class &#145;B&#146; Ordinary Shares outstanding as of April&nbsp;30, 2010. The Percentage After Offering
column assumes the exercise of options for 573,334 Class &#145;A&#146; Ordinary Shares held by the Selling
Shareholders.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We do not know when or in what amounts the selling shareholders may offer shares for sale. The
selling shareholders may not sell all or any of the shares offered by this prospectus.
Consequently, we cannot estimate the number of the shares that will be held by the selling
shareholders after completion of the offering. However, for purposes of the table below, we have
assumed that, after completion of the offering, none of the shares covered by this prospectus as of
the date of this prospectus will be held by the selling shareholders.
</DIV>

<P align="center" style="font-size: 10pt; text-indent: 4%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->7<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">
<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">This prospectus may be amended or supplemented from time to time to add selling shareholders
to or delete the names of selling shareholders from the following list or to otherwise amend or
supplement the information in the table set forth below.
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="23%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="8%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="8%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="8%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Number of</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Number of</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">Number of</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">Number of</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Class &#145;A&#146;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Class</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Class &#145;A&#146;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">Class &#145;B&#146;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">Class</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">Class&#146; B&#146;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Ordinary</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">&#145;A&#146;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Ordinary</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">Ordinary</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">&#145;B&#146;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">Ordinary</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">Percentage</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Shares</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Ordinary</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Shares</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">Shares</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">Ordinary</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">Shares</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">Total</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Beneficially</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Shares</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Beneficially</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">Beneficially</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">Shares</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">Beneficially</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">Voting</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Owned</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">that may</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Owned</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">Owned</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">that may</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">Owned</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">Power</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">Before</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">be</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">After</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">Before</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">be</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">After</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">After</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000">Name</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000">Offering</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000">Offered</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000">Offering</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000">Offering</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000">Offered</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000">Offering</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000">Offering</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Rory Nealon</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">971,664</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">166,668</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">804,998</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">1.0</TD>
    <TD nowrap>%</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">(1)</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">(41,667</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">(201,249</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">(242,916</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">ADS&#146;s)</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">ADS&#146;s)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">ADS&#146;s)</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 0em">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Ronan O&#146;Caoimh</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">5,308,330</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">266,666</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">5,041,664</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">6.0</TD>
    <TD nowrap>%</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">(2)</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">(66,666</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">(1,260,416</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">(1,327,082</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">ADS&#146;s)</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">ADS&#146;s)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">ADS&#146;s)</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 0em; background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Peter Coyne</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">130,000</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">20,000</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">110,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">0.1</TD>
    <TD nowrap>%</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">(3)</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">(5,000</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">(27,500</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">(32,500</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">ADS&#146;s)</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">ADS&#146;s)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">ADS&#146;s)</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 0em">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Jim Walsh</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">1,657,362</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">20,000</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">1,637,362</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">1.9</TD>
    <TD nowrap>%</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">(4)</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">(5,000</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">(409,340</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">(414,340</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">ADS&#146;s)</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">ADS&#146;s)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">ADS&#146;s)</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 0em; background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Denis Burger</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">270,000</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">20,000</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">250,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">0.3</TD>
    <TD nowrap>%</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">(5)</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">(5,000</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">(62,500</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">(67,500</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">ADS&#146;s)</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">ADS&#146;s)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">ADS&#146;s)</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 0em">
    <TD><DIV style="margin-left:15px; text-indent:-15px">James Merselis</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">40,000</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">40,000</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">(6)</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">(10,000</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">(10,000</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">ADS&#146;s)</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">ADS&#146;s)</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 0em; background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Clint Severson</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">88,000</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">40,000</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">48,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">0.1</TD>
    <TD nowrap>%</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">(7)</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">(10,000</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">(12,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">(22,000</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">ADS&#146;s)</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">ADS&#146;s)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">ADS&#146;s)</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body --></TABLE>
</DIV>





<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR style="font-size: 6pt">
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="96">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><B>(1)</B></TD>
    <TD>&nbsp;</TD>
    <TD>Includes 771,664 shares issuable upon exercise of options which are currently exercisable or
become exercisable within 60&nbsp;days of the date of this prospectus.</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left"><B>(2)</B></TD>
    <TD>&nbsp;</TD>
    <TD>Includes 1,470,834 shares issuable upon exercise of options which are currently exercisable or
become exercisable within 60&nbsp;days of the date of this prospectus.</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left"><B>(3)</B></TD>
    <TD>&nbsp;</TD>
    <TD>Includes 130,000 shares issuable upon exercise of options which are currently exercisable or
become exercisable within 60&nbsp;days of the date of this prospectus.</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left"><B>(4)</B></TD>
    <TD>&nbsp;</TD>
    <TD>Includes 263,750 shares issuable upon exercise of options which are currently exercisable or
become exercisable within 60&nbsp;days of the date of this prospectus.</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left"><B>(5)</B></TD>
    <TD>&nbsp;</TD>
    <TD>Includes 130,000 shares issuable upon exercise of options which are currently exercisable or
become exercisable within 60&nbsp;days of the date of this prospectus.</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left"><B>(6)</B></TD>
    <TD>&nbsp;</TD>
    <TD>Includes 40,000 shares issuable upon exercise of options which are currently exercisable or
become exercisable within 60&nbsp;days of the date of this prospectus.</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left"><B>(7)</B></TD>
    <TD>&nbsp;</TD>
    <TD>Includes 40,000 shares issuable upon exercise of options which are currently exercisable or
become exercisable within 60&nbsp;days of the date of this prospectus.</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->8<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">




<DIV align="left">
<A name="106"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>PLAN OF DISTRIBUTION</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The Class &#145;A&#146; Ordinary Shares covered by this prospectus may be offered and sold from time to
time by the selling shareholders. The term &#147;selling shareholders&#148; includes pledgees, donees,
transferees or other successors-in-interest selling shares received after the date of this
prospectus from the selling shareholders as a pledge, gift or other non-sale related transfer. To
the extent required, we may amend and supplement this prospectus from time to time to describe a
specific plan of distribution.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The selling shareholders will act independently of us in making decisions with respect to the
timing, manner and size of each sale. The selling shareholders may make these sales at prices and
under terms then prevailing or at prices related to the then current market price. The selling
shareholders may also make sales in negotiated transactions, including pursuant to one or more of
the following methods:
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>purchases by a broker-dealer as principal and resale by such broker-dealer for its own
account pursuant to this prospectus;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>ordinary brokerage transactions and transactions in which the broker solicits purchasers;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>one or more block trades in which the broker-dealer will attempt to sell the shares as
agent but may position and resell a portion of the block as principal to facilitate the
transaction;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>an over-the-counter distribution in accordance with the rules of The Nasdaq Stock Market;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>through brokers pursuant to pre-arranged sales plans intended to qualify under Rule l0b5-1
of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;);</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>in privately negotiated transactions;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>in any combination of one or more of these methods; and</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>in any other lawful method.</TD>
</TR>


</TABLE>
</DIV>
<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->9<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV style="margin-top: 10pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In connection with distributions of the Class &#145;A&#146; Ordinary Shares or otherwise, the selling
shareholders may:
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>enter into hedging transactions with broker-dealers or other financial institutions, which
may in turn engage in short sales of the shares in the course of hedging the positions they
assume;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>sell the shares short and redeliver the shares to close out such short positions;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>enter into option or other transactions with broker-dealers or other financial institutions
that require the delivery to them of shares offered by this prospectus, which they may in turn
resell; and</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>pledge shares to a broker-dealer or other financial institution, which, upon a default,
they may in turn resell.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In addition, the selling shareholders may sell all or a portion of the Class &#145;A&#146; Ordinary
Shares that qualify for sale pursuant to Rule&nbsp;144 or 145 under the Securities Act of 1933 (the
&#147;Securities Act&#148;) rather than pursuant to this prospectus.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Sales through brokers may be made by any method of trading authorized by any stock exchange or
market on which the shares may be listed or quoted, including block trading in negotiated
transactions.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Without limiting the foregoing, such brokers may act as dealers by purchasing any or all of
the Class &#145;A&#146; Ordinary Shares covered by this prospectus, either as agents for others or as
principals for their own accounts, and reselling such shares pursuant to this prospectus. The
selling shareholders may effect such transactions directly, or indirectly through underwriters,
broker-dealers or agents acting on their behalf. In effecting sales, broker-dealers or agents
engaged by the selling shareholder may arrange for other broker-dealers to participate.
Broker-dealers or agents may receive commissions, discounts or concessions from the selling
shareholders, in amounts to be negotiated immediately prior to the sale.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In offering the Class &#145;A&#146; Ordinary Shares covered by this prospectus, the selling
shareholders, and any broker-dealers and any other participating broker-dealers who execute sales
for the selling shareholders, may be deemed to be &#147;underwriters&#148; within the meaning of the
Securities Act in connection with these sales. Any profits realized by the selling shareholders and
the compensation of such broker-dealers may be deemed to be underwriting discounts and commissions.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In order to comply with the securities laws of certain states, the Class &#145;A&#146; Ordinary Shares
must be sold in those states only through registered or licensed brokers or dealers. In addition,
in certain states the shares may not be sold unless they have been registered or qualified for sale
in the applicable state or an exemption from the registration or qualification requirement is
available and is complied with.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We have advised the selling shareholders that the anti-manipulation rules of Regulation&nbsp;M
under the Exchange Act may apply to sales of Class &#145;A&#146; Ordinary shares in the market and to the
activities of the selling shareholders and their respective affiliates. In addition, we will make
copies of this prospectus available to the selling shareholders for the purpose of satisfying the
prospectus delivery requirements of the Securities Act. The selling shareholders may indemnify
any broker-dealer that participates in transactions involving the sale of the shares against
certain liabilities, including liabilities arising under the Securities Act.
</DIV>
<P align="center" style="font-size: 10pt; text-indent: 4%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->10<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">All costs, expenses and fees in connection with the registration of the shares offered hereby
will be borne by us. Brokerage commissions and similar selling expenses, if any, attributable to
the sale of shares will be borne by the selling shareholders.
</DIV>
<DIV align="left">
<A name="107"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>LIMITATION OF LIABILITY AND INDEMNIFICATION MATTERS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Our Articles of Association provide that every Director, Managing Director, agent secretary or
other officer of Trinity Biotech shall be entitled to be indemnified out of the assets of Trinity
Biotech against all losses or liabilities which he may sustain or incur in or about the execution
of the duties of his office or otherwise in relation thereto, including any liability incurred by
him in defending any proceeding, whether civil or criminal, in which judgment is given in his favor
or in which he is acquitted, and no Director or other officer shall be liable for any loss, damage
or misfortune which may happen to or be incurred by Trinity Biotech in the execution of the duties
of his office or in relation thereto.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Insofar as indemnification for liabilities arising under the Securities Act may be permitted
to directors, officers or persons controlling the registrant pursuant to the foregoing provisions,
the registrant has been informed that in the opinion of the Securities and Exchange Commission such
indemnification is against public policy as expressed in the Act and is therefore unenforceable.
</DIV>
<P align="center" style="font-size: 10pt; text-indent: 4%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->11<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">
<DIV align="left">
<A name="108"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>LEGAL MATTERS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The validity of the Class &#145;A&#146; Ordinary Shares offered by this prospectus has been passed upon
for us by William Fry, Dublin, Ireland.
</DIV>
<DIV align="left">
<A name="109"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>EXPERTS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The consolidated financial statements as of 31 December&nbsp;2009 and 31 December&nbsp;2008 and for each
of the years in the two year period ended 31 December&nbsp;2009 incorporated in this prospectus by
reference from Trinity Biotech&#146;s Annual Report on Form 20-F for the year ended December&nbsp;31, 2009 as
well as the effectiveness of internal control over financial reporting as of December&nbsp;31, 2009 have
been audited by Grant Thornton, an independent registered public accounting firm, as stated in its
reports, which are incorporated herein by reference.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The consolidated statements of operations, recognized income and expenses and cash flows of
Trinity Biotech plc and subsidiaries for the year ended December&nbsp;31, 2007 have been incorporated by
reference herein and in the registration statement in reliance upon the report of KPMG, an
independent registered public accounting firm, from Trinity Biotech&#146;s Annual Report on Form 20-F
for the year ended December&nbsp;31, 2009, and upon the authority of said firms as experts in accounting
and auditing.
</DIV>

<DIV align="left">
<A name="110"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>WHERE YOU CAN FIND MORE INFORMATION</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">We file annual and special reports and other information with the SEC. You may obtain these
filings over the internet at the SEC&#146;s web site at http://www.sec.gov. You may also read and copy
these filings at the SEC&#146;s public reference room at 450 Fifth Street, N.W., Washington, D.C. 20549.
You may obtain information on the operation of the public reference room by calling the SEC at
1-800-SEC-0330, and may obtain copies of Trinity Biotech&#146;s filings from the public reference room
by calling (202)&nbsp;942-8090. Our internet address is http://www.trinitybiotech.com.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Trinity Biotech is a &#147;foreign private issuer&#148; as defined in Rule&nbsp;3b-4 under the Exchange Act.
As a result, our proxy solicitations are not subject to the disclosure and procedural requirements
of Regulation&nbsp;14A under the Exchange Act and transactions in Trinity Biotech&#146;s equity securities by
its officers and directors are exempt from Section&nbsp;16 of the Exchange Act. In addition, Trinity
Biotech is not required under the Exchange Act to file periodic reports and financial statements as
frequently or as promptly as U.S. companies whose securities are registered under the Exchange Act.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Our ADSs are listed for quotation on the Nasdaq National Cap Market, and reports and other
information filed by us can be inspected at the offices of Nasdaq. Each ADS represents four Class&nbsp;A
Ordinary Shares of Trinity Biotech.
</DIV>

<P align="center" style="font-size: 10pt; text-indent: 4%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->12<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">


<DIV align="left">
<A name="111"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The Securities and Exchange Commission regulations allow us to &#147;incorporate by reference&#148;
information into this prospectus, which means that we can disclose important information to you by
referring you to another document filed separately with the Securities and Exchange Commission. The
information incorporated by reference is considered part of this prospectus. Information
incorporated by reference from earlier documents is superseded by information set forth herein and
information that has been incorporated by reference from more recent documents.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The following documents filed by us with the Securities and Exchange Commission are
incorporated in this prospectus by reference:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">(a)&nbsp;The Company&#146;s Annual Report on Form 20-F for the year ended December&nbsp;31, 2009 filed on
April&nbsp;15, 2010.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">(b)&nbsp;All other reports filed by the Company with the Commission pursuant to Sections 13(a) or
15(d) of the 1934 Act, since December&nbsp;31, 2009.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">(c)&nbsp;A description of the ADSs and the Class &#145;A&#146; Ordinary Shares is contained in Amendment No.
5 to the Company&#146;s Registration Statement on Form F-1 (File No.&nbsp;333-48556) and in Item&nbsp;10 in the
Company&#146;s
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In addition, all documents subsequently filed by the Company pursuant to Section&nbsp;13(a), 13(c),
14 or 15(d) of the Exchange Act, prior to the filing of a post-effective amendment to the
Registration Statement to which this prospectus pertains which indicates that all securities
offered hereby have been sold, or which deregisters all such securities then remaining unsold,
shall be deemed to be incorporated by reference in and made a part of the Registration Statement to
which this prospectus pertains from the date of filing of such documents.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Copies of any documents that are incorporated by reference herein, other than exhibits to such
documents, may be obtained upon request without charge by written or oral request from the
Company&#146;s Corporate Secretary, Trinity Biotech plc, IDA Business Park, Bray, Co. Wicklow, Ireland.
The Company&#146;s telephone number is &#043;353 1 276 9800.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">You should rely only on the information contained or incorporated by reference in this
prospectus. We have not authorized anyone to provide you with information that is different from
what is contained in this prospectus. This prospectus is dated May&nbsp;6, 2010. You should not assume
that the information contained in this prospectus is accurate as of any date other than that date.
</DIV>


<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->13<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">



<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>573,334 CLASS &#145;A&#146; ORDINARY SHARES<BR>
(143,333 ADS Equivalent)</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>TRINITY BIOTECH PLC</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>Class &#145;A&#146; Ordinary Shares</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>PROSPECTUS</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>May&nbsp;6, 2010</B>
</DIV>



<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">



<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>PART II</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>INFORMATION REQUIRED IN THE REGISTRATION STATEMENT</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Item&nbsp;3. Incorporation of Documents by Reference</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The following documents which have been filed by the Company (File No.&nbsp;0-22320) with the
Securities and Exchange Commission (the &#147;Commission&#148;), pursuant to the Securities Exchange Act of
1934, as amended (the &#147;1934 Act&#148;) are incorporated by reference herein and shall be deemed to be a
part hereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">(a)&nbsp;The Company&#146;s Annual Report on Form 20-F for the year ended December&nbsp;31, 2009 filed on
April&nbsp;15, 2010.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">(b)&nbsp;All other reports filed by the Company with the Commission pursuant to Sections 13(a) or
15(d) of the 1934 Act, since December&nbsp;31, 2009.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">(c)&nbsp;A description of the ADSs and the Class &#145;A&#146; Ordinary Shares is contained in Amendment No.
5 to the Company&#146;s Registration Statement on Form F-1 (File No.&nbsp;333-48556) and in Item&nbsp;10 in the
Company&#146;s Annual Report on Form 20-F for the fiscal year ended December&nbsp;31, 2008.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">In addition, all documents subsequently filed by the Company pursuant to Section&nbsp;13(a), 13(c),
14 or 15(d) of the Exchange Act, prior to the filing of a post-effective amendment to this
Registration Statement which indicates that all securities offered hereby have been sold, or which
deregisters all such securities then remaining unsold, shall be deemed to be incorporated by
reference in and made a part of this Registration Statement from the date of filing of such
documents. Any statement contained in a document incorporated by reference shall be deemed to be
modified or superceded for purposes of this Registration Statement to the extent that it conflicts
with a statement contained herein or in any other subsequently filed document which also is or is
deemed to be incorporated by reference, and such statement shall not be deemed, except so modified
or superceded, to constitute a part of this Registration Statement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Copies of any documents that are incorporated by reference herein, other than exhibits to such
documents, may be obtained upon request without charge by written or oral request from the
Company&#146;s Corporate Secretary, Trinity Biotech plc, IDA Business Park, Bray, Co. Wicklow, Ireland.
The Company&#146;s telephone number is 011 353 1 276 9800.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Item&nbsp;4. Description of Securities</B>
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 4%">Not applicable.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Item&nbsp;5. Interests of Named Experts and Counsel</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Not applicable.
</DIV>
<P align="center" style="font-size: 10pt; text-indent: 4%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->II-1<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Item&nbsp;6. Indemnification of Directors and Officers</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">The Company&#146;s Articles of Association provide that every Director, Managing Director, agent
secretary or other officer of the Company shall be entitled to be indemnified out of the assets of
the Company against all losses or liabilities which he may sustain or incur in or about the
execution of the duties of his office or otherwise in relation thereto, including any liability
incurred by him in defending any proceeding, whether civil or criminal, in which judgment is given
in his favor or in which he is acquitted, and no Director or other officer shall be liable for any
loss, damage or misfortune which may happen to or be incurred by the Company in the execution of
the duties of his office or in relation thereto.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Item&nbsp;7. Exemption from Registration Claimed &#151; Not applicable.</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Item&nbsp;8. Exhibits</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="77%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">4.</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Employee Share Option Plan 2006</DIV></TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">5.</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Opinion of William Fry</DIV></TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">23.1</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Consent of Grant Thornton, Independent Registered Public Accounting Firm</DIV></TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">23.2</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Consent of KPMG, Independent Registered Public Accounting Firm</DIV></TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">23.3</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Consent of William Fry (included in Exhibit&nbsp;5)</DIV></TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">24</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Powers of Attorney (included in signature pages)</DIV></TD>
</TR>
<!-- End Table Body --></TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Item&nbsp;9. Undertakings</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">(A)&nbsp;The undersigned registrant hereby undertakes:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 4%; text-indent: 4%">(1)&nbsp;To file, during any period in which offers or sales are being made, a
post-effective amendment to this registration statement:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 4%; text-indent: 4%">(i)&nbsp;To include any prospectus required by Section&nbsp;10(a)(3) of the Securities Act of
1933;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 4%; text-indent: 4%">(ii)&nbsp;To reflect in the prospectus any facts or events arising after the effective date
of the registration statement (or the most recent post-effective amendment thereof) which,
individually or in the aggregate, represent a fundamental change in the information set
forth in the registration statement. Notwithstanding the foregoing, any increase or decrease
in volume of securities offered (if the total dollar value of securities offered would not
exceed that which was registered) and any deviation from the low or high end of the
estimated maximum offering range may be reflected in the form of prospectus filed with the
Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price
represent no more than a 20&nbsp;percent change in the maximum approximate
offering price set forth in the Calculation of Registration Fee table in the effective
registration statement.
</DIV>
<P align="center" style="font-size: 10pt; text-indent: 4%">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->II-2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 4%; text-indent: 4%">(iii)&nbsp;To include any material information with respect to the plan of distribution not
previously disclosed in the registration statement or any material change to such
information in the registration statement;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>Provided, however, </I>that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information
required to be included in a post-effective amendment by those paragraphs is contained in periodic
reports filed with or furnished to the Commission by the registrant pursuant to section 13 or
section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the
registration statement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 4%; text-indent: 4%">(2)&nbsp;That, for the purpose of determining any liability under the Securities Act of
1933, each such post-effective amendment shall be deemed to be a new registration statement
relating to the securities offered therein, and the offering of such securities at that time
shall be deemed to be the initial <I>bona fide </I>offering thereof
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 4%; text-indent: 4%">(3)&nbsp;To remove from registration by means of a post-effective amendment any of the
securities being registered which remain unsold at the termination of the offering.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">(B)&nbsp;The undersigned registrant hereby undertakes that, for the purposes of determining any
liability under the Securities Act of 1933, each filing of the registrant&#146;s annual report pursuant
to section 13(a) or section 15(d) of the Securities Exchange Act of 1934 (and, where applicable,
each filing of an employee benefit plan&#146;s annual report pursuant to section 15(d) of the Securities
Exchange Act of 1934) that is incorporated by reference in the registration statement shall be
deemed to be a new registration statement relating to the securities offered therein, and the
offering of such securities at that time shall be deemed to be the initial bona fide offering
thereof
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">(C)&nbsp;Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be
permitted to directors, officers and controlling persons of the Registrant pursuant to the
foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the
Securities and Exchange Commission such indemnification is against public policy as expressed in
the Act and is, therefore, unenforceable. In the event that a claim for indemnification against
such liabilities (other than the payment by the registrant of expenses incurred or paid by a
director, officer or controlling person of the registrant in the successful defense of any action,
suit or proceeding) is asserted by such director, officer or controlling person in connection with
the securities being registered, the registrant will, unless in the opinion of its counsel the
matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the
question whether such indemnification by it is against public policy as expressed in the Act and
will be governed by the final adjudication of such issue.
</DIV>


<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->II-3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">



<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>SIGNATURES</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it
has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and
has duly caused this Registration Statement to be signed on its behalf by the undersigned,
thereunto duly authorized, in Dublin, Ireland on the 6<SUP style="font-size: 85%; vertical-align: text-top">th</SUP> day of May, 2010.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="45%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="45%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" valign="top" align="left">TRINITY BIOTECH PLC</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Kevin Tansley
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Kevin Tansley
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Chief Financial Officer</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body --></TABLE>
</DIV>



<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->II-4<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">



<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>POWER OF ATTORNEY</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Each person whose signature appears below hereby constitutes Kevin Tansley his true and lawful
attorney-in-fact with full power to execute in the name of such person, in the capacities stated
below, and to file, such one or more amendments to this Registration Statement as the Registrant
deems appropriate, and generally to do all such things in the name and on behalf of such person, in
the capacities stated below, to enable the Registrant to comply with the provisions of the
Securities Act of 1933, as amended, and all requirements of the Securities and Exchange Commission
thereunder, and hereby ratifies and confirms the signature of such person as it may be signed by
such attorney-in-fact to any and all amendments to this Registration Statement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">Pursuant to the requirements of the Securities Act of 1933, this Registration Statement and
the above power of attorney have been signed below by the following persons in the capacities
indicated on May&nbsp;6, 2010.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="35%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="45%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Signature</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Title</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">/s/ Ronan O&#146;Caoimh
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Ronan O&#146;Caoimh
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Chief Executive Officer<BR>

(Principal Executive Officer and Director)&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">/s/ Denis Burger
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Denis Burger
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Non-executive Director<BR>

(Authorized U.S. representative)&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">/s/ Rory Nealon
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Rory Nealon
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Chief Operations Officer and Director&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">/s/ Kevin Tansley
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Kevin Tansley
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Chief Financial Officer and Company Secretary&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Non-executive Director</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Peter Coyne
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Non-executive Director</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
James D. Merselis
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Non-executive Director</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Clint Severson
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">/s/ James Walsh
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
James Walsh
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Non-executive Director&nbsp;</TD>
</TR>
<!-- End Table Body --></TABLE>
</DIV>



<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->II-5<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">



<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>INDEX OF EXHIBITS</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="77%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">4.</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>

<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Employee Share Option Plan 2006*</DIV></TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">5.</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Opinion of William Fry</DIV></TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">23.1</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Consent of Grant Thornton, Independent Registered Public Accounting Firm</DIV></TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">23.2</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Consent of KPMG, Independent Registered Public Accounting Firm</DIV></TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">23.3</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Consent of William Fry (included in Exhibit&nbsp;5)</DIV></TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">24</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Powers of Attorney (included in signature pages)</DIV></TD>
</TR>
<!-- End Table Body --></TABLE>
</DIV>

<DIV align="left"><DIV style="font-size: 10pt; margin-top: 10pt; width: 18%; border-bottom: 1px solid #000000">&nbsp;</DIV></DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR style="font-size: 6pt">
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="96">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD nowrap align="left">*</TD>
    <TD>&nbsp;</TD>
    <TD>Incorporated by reference to Exhibit&nbsp;4 of the
registrant&#146;s annual report on Form 20-F for the year ended December&nbsp;31, 2009.</TD>
</TR>

</TABLE>



<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->II-6<!-- /Folio -->
</DIV>



</BODY>
</HTML>
[{"type": "S-8", "sequence": "1", "filename": "c00479sv8.htm", "description": "FORM S-8", "secsgml_size_bytes": 139144}]
{"company-data": {"conformed-name": "TRINITY BIOTECH PLC", "cik": "0000888721", "assigned-sic": "2835", "irs-number": "000000000", "state-of-incorporation": "L2", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "S-8", "act": "33", "file-number": "333-166590", "film-number": "10808370"}, "business-address": {"street1": "IDA BUSINESS PARK, BRAY, CO WICKLOW", "street2": "IRELAND", "city": "DUBLIN IRELAND", "state": "L2", "zip": "18", "phone": "01135312955111"}, "mail-address": {"street1": "3 ROCK ROAD", "street2": "SANDYFORD INDUSTRIAL ESTATES", "city": "DUBLIN IRELAND", "state": "L2", "zip": "18"}}
Form S-8
Table of Contents
As filed with the Securities and Exchange Commission on May 6, 2010
Registration
No. 333-____
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933
TRINITY BIOTECH PLC
(Exact name of Registrant as specified in its charter)
Republic of Ireland
Not Applicable
(State or other jurisdiction of
(I.R.S. Employer
incorporation or organization)
Identification No.)
IDA Business Park
Bray, Co. Wicklow
Ireland
011 353 1 276 9800
(Address of Registrant's principal executive offices)
TRINITY BIOTECH PLC EMPLOYEE SHARE OPTION PLAN 2006
(full title of the plan)
Alan J. Bernstein, Esq.
Carter Ledyard & Milburn LLP
2 Wall Street
New York, NY 10005
(212) 732-3200
(Name and address of agent for service)
(Telephone number, including area code, of agent for service)
Copies to:
Alan J. Bernstein, Esq.
Carter Ledyard & Milburn LLP
2 Wall Street
New York, NY 10005
(212) 732-3200
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated
filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.
(Check one):
Large accelerated filer
o
Accelerated filer
þ
Non-accelerated filer
o
Smaller reporting company
o
(Do not check if a smaller reporting company)
CALCULATION OF REGISTRATION FEE
Proposed
Proposed
maximum
maximum
Amount to be
offering price
aggregate
Amount of
Title of securities to be registered
registered
per share
offering price
registration fee
Class A Ordinary
Shares represented
by American
Depository Shares
(1)
5,000,000 (2)
$5.98 (3)
$29,900,000 (3)
$
2,131.87
(1)
American Depositary Shares ("ADS"), each ADS representing four Class A Ordinary Shares,
nominal value US$0.0109 per share ("Common Stock") of Trinity Biotech plc (the "Company"),
have been registered on a separate Registration Statement on Form F-6.
(2)
The 5,000,000 Class A Ordinary Shares represent the number of shares issuable under the
Employee Share Option Plan 2006 (the "Plan").
(3)
Calculated pursuant to Rule 457(c) under the Securities Act of 1933, on the basis of the
average of the high and low prices ($6.19 and $5.77) of an ADR, as quoted on the NASDAQ
Capital Market on May 5, 2010.
This Registration Statement shall become effective immediately upon filing as provided in Rule
462(a) under the Securities Act of 1933.
Table of Contents
PART I
INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS
Item 1. Plan Information*
Item 2. Registrant Information and Employee Plan Annual Information*
*
This information is not required to be included in, and is not incorporated by reference in, this
Registration Statement.
Table of Contents
REOFFER PROSPECTUS
573,334 CLASS 'A' ORDINARY SHARES
(143,333 ADS Equivalent)
TRINITY BIOTECH PLC
CLASS 'A' ORDINARY SHARES
REPRESENTED BY AMERICAN DEPOSITARY SHARES
This prospectus is being used for the offering and sale from time to time by the selling
shareholders identified on page 8 of this prospectus of up to a maximum of 573,334 Class 'A'
Ordinary Shares (four Class 'A' Ordinary Shares represented by one American Depository Share
("ADS")) that have been issued under stock options previously granted under our 2006 Employee Stock
Option Plan (the "Plan").
The selling shareholders, or their pledgees, donees, transferees or other
successors-in-interest, may offer the shares through public or private transactions, at prevailing
market prices or at privately negotiated prices. The selling shareholders will receive all of the
net proceeds from the sale of the shares. We will not receive any proceeds from the sale of the
shares. All costs, expenses and fees in connection with the registration of the shares offered
hereby will be borne by us. Brokerage commissions and similar selling expenses, if any,
attributable to the sale of shares will be borne by the selling shareholders.
Our ADSs are listed on the Nasdaq National Cap Market under the symbol "TRIB." On May 5, 2010,
the last sale price of our ADSs as reported by the Nasdaq National Cap Market was $5.94 per share.
Investing in our shares involves significant risks. You should read the "Risk Factors" section
beginning on page 1 of this prospectus before investing.
Neither the U.S. Securities and Exchange Commission nor any state securities commission has
approved or disapproved of these securities or determined if this prospectus is truthful or
complete. Any representation to the contrary is a criminal offense.
The date of this Prospectus is May 6, 2010
TABLE OF CONTENTS
SUMMARY
1
RISK FACTORS
1
NOTE REGARDING FORWARD-LOOKING STATEMENTS
6
USE OF PROCEEDS
7
SELLING SHAREHOLDERS
7
PLAN OF DISTRIBUTION
9
LIMITATION OF LIABILITY AND INDEMNIFICATION MATTERS
11
LEGAL MATTERS
12
EXPERTS
12
WHERE YOU CAN FIND MORE INFORMATION
12
INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE
13
Exhibit 5
Exhibit 23.1
Exhibit 23.2
i
Table of Contents
SUMMARY
You should rely only on the information contained in this prospectus or incorporated by
reference into this prospectus. We have not authorized any other person to provide you with
different information. The information contained in this prospectus is accurate only as of the date
of this prospectus, regardless of the time of delivery of this prospectus or of any sale of shares.
This prospectus does not constitute an offer to sell, or a solicitation of an offer to buy,
nor shall there be any sale of these shares by any person in any jurisdiction in which it is
unlawful for that person to make such an offer, solicitation or sale.
Whenever we refer to "Trinity Biotech" or to "us," or use the terms "we" or "our" in this
prospectus, we are referring to Trinity Biotech plc an Irish public limited company, and its
consolidated subsidiaries. To understand this offering fully, you should read this entire document
carefully, including particularly the "Risk Factors" section, as well as the documents identified
in the section titled "Where you Can Find More Information."
About Trinity Biotech
Trinity Biotech plc, an Irish public limited company, was formed in January 1992 to acquire,
develop, manufacture and market rapid and laboratory based diagnostic tests for the detection of
various infectious diseases, blood coagulation disorders and other medical conditions. In addition,
we manufacture, acquire and market diagnostic tests and antibodies through our Irish, UK and German
subsidiaries as well as our U.S. subsidiaries, Clark Laboratories Inc. (trading as Trinity Biotech
(USA) Corp.), MarDx Diagnostics Inc., Biopool U.S., Inc., Primus Corporation and Fitzgerald
Industries International, Inc. Our address is IDA Business Park, Bray, Co. Wicklow, Ireland,
telephone number +353 1 276 9800.
RISK FACTORS
You should carefully consider the risk factors listed below. These risk factors may cause our
future earnings or our financial condition to be less favorable than we expect. This list includes
only the risk factors that we believe are most important and is not a complete list of risks. Other
risks may be significant, and the risks listed below may affect us to a greater extent than
indicated. You should read this section together with the other information in this prospectus and
the documents that are incorporated into this prospectus be reference.
Trinity Biotech's operating results may be subject to fluctuations.
•
Trinity Biotech's operating results may fluctuate as a result of many factors related to
its business, including the competitive conditions in the industry, major reorganisations of
the group's activities, loss of significant customers, delays in the development of new
products and currency fluctuations, as described in more detail below, and general factors
such as the size and timing of orders, the prevalence of various diseases and general economic
conditions. In the event of lower operating profits, this could have a negative impact on cash
generated from operations and also negatively impact shareholder value.
Table of Contents
A need for capital might arise in the future if Trinity Biotech's capital requirements increase or
revenues decrease.
•
Up to now Trinity Biotech has funded its operations through the sale of its shares and
securities convertible into shares, cash flows from operations and bank borrowings. Trinity
Biotech expects that the proceeds of equity financings, bank borrowings, lease financing,
current working capital and sales revenues will fund its existing operations and payment
obligations. However, if our capital requirements are greater than expected, or if our
revenues do not generate sufficient cashflows to fund our operations, we may need to find
additional financing which may not be available on attractive terms or at all. Any future
financing could have an adverse effect on our current shareholders or the price of our shares
in general.
Trinity Biotech's acquisition strategy may be less successful than expected, and therefore, growth
may be limited.
•
Trinity Biotech has historically grown organically and through the acquisition of, and
investment in, other companies, product lines and technologies. There can be no guarantees
that recent or future acquisitions can be successfully assimilated or that projected growth in
revenues or synergies in operating costs can be achieved. Our ability to integrate future
acquisitions may also be adversely affected by inexperience in dealing with new technologies,
and changes in regulatory or competitive environments. Additionally, even during a successful
integration, the investment of management's time and resources in the new enterprise may be
detrimental to the consolidation and growth of our existing business.
The diagnostics industry is highly competitive, and Trinity Biotech's research and development
could be rendered obsolete by technological advances of competitors.
•
Trinity Biotech's principal business is the supply of medical diagnostic test kits and
related diagnostic instrumentation. The diagnostics industry is extremely competitive. Trinity
Biotech is competing directly with companies which have greater capital resources and larger
marketing and business organisations than Trinity Biotech. Trinity Biotech's ability to grow
revenue and earnings may be adversely impacted by competitive product and pricing pressures
and by its inability to gain or retain market share as a result of the action of competitors.
•
We have invested in research and development ("R&D") but there can be no guarantees that
our R&D programmes will not be rendered technologically obsolete or financially non-viable by
the technological advances of our competitors, which would also adversely affect our existing
product lines and inventory. The main competitors of Trinity Biotech (and their principal
products with which Trinity Biotech competes) include Siemens (Sysmex
®
CA, D-Dimer plus,
Enzygnost
®
), Inverness Medical Innovations, Inc. (Determine™ , Wampole™, Athena™), Diasorin
Inc. (Liasion™, ETI™), Abbott Diagnostics (AxSYM™, IMx™), Diagnostic Products Corp. — DPC
(Immulite™), Bio-Rad (ELISA, WB Bioplex™ & A1c), Roche Diagnostics (COBAS AMPLICOR™,
Ampliscreen™, Accutrend™) and OraSure Technologies, Inc (OraQuick
®
).
2
Table of Contents
Trinity Biotech is highly dependent on suitable distributors worldwide.
•
Trinity Biotech currently distributes its product portfolio through distributors in
approximately 75 countries worldwide. Our continuing economic success and financial security
is dependent on our ability to secure effective channels of distribution on favourable trading
terms with suitable distributors.
Trinity Biotech's business could be adversely affected by changing market conditions resulting in
the reduction of the number of institutional customers.
•
The diagnostics industry is in transition with a number of changes that affect the market
for diagnostic test products. Changes in the healthcare industry delivery system have resulted
in major consolidation among reference laboratories and in the formation of multi-hospital
alliances, reducing the number of institutional customers for diagnostic test products. There
can be no assurance that we will be able to enter into and/or sustain contractual or other
marketing or distribution arrangements on a satisfactory commercial basis with these
institutional customers.
Trinity Biotech's long-term success depends on its ability to develop new products subject to
stringent regulatory control. Even if new products are successfully developed, Trinity Biotech's
proprietary know-how, manufacturing techniques and trade secrets may be copied by competitors.
Furthermore, Trinity Biotech's patents have a limited life time and are thereafter subject to
competition with generic products. Also, competitors might claim an exclusive patent for products
Trinity Biotech plans to develop.
•
We are committed to significant expenditure on R&D. However, there is no certainty that
this investment in research and development will yield technically feasible or commercially
viable products. Our organic growth and long-term success is dependent on our ability to
develop and market new products but this work is subject to very stringent regulatory control
and very significant costs in research, development and marketing. Failure to introduce new
products could significantly slow our growth and adversely affect our market share.
•
Even when products are successfully developed and marketed, Trinity Biotech's ownership of
the technology behind these products has a finite life. In general, generic competition, which
can arise through replication of the Trinity Biotech's proprietary know-how, manufacturing
techniques and trade secrets or after the expiration of a patent, can have a detrimental
effect on a product's revenue, profitability and market share. There can be no guarantee that
the net income and financial position of Trinity Biotech will not be adversely affected by
competition from generic products. Conversely, on occasion, certain companies have claimed
exclusive patent, copyright and other intellectual property rights to technologies in the
diagnostics industry. If these technologies relate to Trinity Biotech's planned products,
Trinity Biotech would be obliged to seek licences to use this technology and, in the event of
being unable to obtain such licences or it being obtainable on grounds that would be
materially disadvantageous to Trinity Biotech, we would be precluded from marketing such
products, which could adversely impact our revenues, sales and financial position.
3
Table of Contents
Trinity Biotech's patent applications could be rejected or the existing patents could be
challenged; our technologies could be subject to patent infringement claims; and trade secrets and
confidential know-how could be obtained by competitors.
•
We can provide no assurance that the patents Trinity Biotech may apply for will be obtained
or that existing patents will not be challenged. The patents owned by Trinity Biotech and its
subsidiaries may be challenged by third parties through litigation and could adversely affect
the value of our patents. We can provide no assurance that our patents will continue to be
commercially valuable.
•
Trinity Biotech currently owns 15 US patents with remaining patent lives varying from less
than one year to 13 years. In addition to these US patents, Trinity Biotech owns a total of 8
additional non-US patents with expiration dates varying between the years 2010 and 2023.
•
Also, our technologies could be subject to claims of infringement of patents or proprietary
technology owned by others. The cost of enforcing our patent and technology rights against
infringers or defending our patents and technologies against infringement charges by others
may be high and could adversely affect our business.
•
Trade secrets and confidential know-how are important to our scientific and commercial
success. Although we seek to protect our proprietary information through confidentiality
agreements and other contracts, we can provide no assurance that others will not independently
develop the same or similar information or gain access to our proprietary information.
Trinity Biotech's business is heavily regulated and non-compliance with applicable regulations
could reduce revenues and profitability.
•
Our manufacturing and marketing of diagnostic test kits are subject to government
regulation in the United States of America by the Food and Drug Administration ("FDA"), and by
comparable regulatory authorities in other jurisdictions. The approval process for our
products, while variable across countries, is generally lengthy, time consuming, detailed and
expensive. Our continued success is dependent on our ability to develop and market new
products, some of which are currently awaiting approval from these regulatory authorities.
There is no certainty that such approval will be granted or, even once granted, will not be
revoked during the continuing review and monitoring process.
•
We are required to comply with extensive post market regulatory requirements.
Non-compliance with applicable regulatory requirements of the FDA or comparable foreign
regulatory bodies can result in enforcement action which may include recalling products,
ceasing product marketing, paying significant fines and penalties, and similar actions that
could limit product sales, delay product shipment, and adversely affect profitability.
4
Table of Contents
Trinity Biotech's success is dependent on certain key management personnel.
•
Trinity Biotech's success is dependent on certain key management personnel. Our key
employees at December 31, 2009 were Ronan O'Caoimh, our CEO and Chairman, Rory Nealon, our
COO, and Kevin Tansley, our CFO and Company Secretary. Competition for qualified employees
among biotechnology companies is intense, and the loss of such personnel or the inability to
attract and retain the additional highly skilled employees required for the expansion of our
activities, could adversely affect our business. In the USA, the UK, France and Germany we
have been able to attract and retain qualified personnel. In Ireland, we have experienced some
difficulties in attracting and retaining staff due to competition from other employers in our
industry.
Trinity Biotech is dependent on its suppliers for the primary raw materials required for its test
kits.
•
The primary raw materials required for Trinity Biotech's test kits consist of antibodies,
antigens or other reagents, glass fibre and packaging materials which are acquired from third
parties. Although Trinity Biotech does not expect to be dependent upon any one source for
these raw materials, alternative sources of antibodies with the characteristics and quality
desired by Trinity Biotech may not be available. Such unavailability could affect the quality
of our products and our ability to meet orders for specific products.
Trinity Biotech may be subject to liability resulting from its products or services.
•
Trinity Biotech may be subject to claims for personal injuries or other damages resulting
from its products or services. Trinity Biotech has global product liability insurance in place
for its manufacturing subsidiaries up to a maximum of
€
6,500,000 (about US$9,555,000) for any
one accident, limited to a maximum of
€
6,500,000 (about US$9,555,000) in any one year period
of insurance. A deductible of US$25,000 is applicable to each insurance event that may arise.
There can be no assurance that our product liability insurance is sufficient to protect us
against liability that could have a material adverse effect on our business.
Currency fluctuations may adversely affect our earnings and assets.
•
Trinity Biotech records its transactions primarily in US Dollars and Euro and prepares its
financial statements in US Dollars. A substantial portion of our expenses are denominated in
Euro. However, Trinity Biotech's revenues are primarily denominated in US Dollars. As a
result, the Group is affected by fluctuations in currency exchange rates, especially the
exchange rate between the US dollar and the Euro, which may adversely affect our earnings and
assets. The percentage of 2009 consolidated revenue denominated in US Dollars was
approximately 72%. Of the remaining 28% revenue, 22% relates to revenue denominated in Euro
and 6% relates to sterling and yen denominated revenues. Thus, a 10% decrease in the value of
the Euro would have approximately a 2% adverse impact on consolidated revenues.
5
Table of Contents
•
As part of the process of mitigating foreign exchange risk, the principal exchange risk
identified by Trinity Biotech is with respect to fluctuations in the Euro. This is
attributable to the level of Euro denominated expenses exceeding the level of Euro denominated
revenues thus creating a Euro deficit. Trinity Biotech continuously monitors its exposure to
foreign currency movements and based on expectations on future exchange rate exposure
implements a hedging policy which may include covering a portion of this exposure through the
use of forward contracts. In the medium term, our objective is to increase the level of non-US
Dollar denominated revenue, thus creating a natural hedge of the non-US Dollar expenditure.
The conversion of our outstanding employee share options and warrants would dilute the ownership
interest of existing shareholders.
•
The warrants issued in 2008 and the total share options exercisable at April 30, 2010 are
convertible into ADSs, 1 ADS representing 4 Class 'A' Ordinary Shares. The exercise of the
share options exercisable and of the warrants will likely occur only when the conversion price
is below the trading price of our ADSs and will dilute the ownership interests of existing
shareholders. For instance, should the options and warrant holders of the 6,408,742 Class 'A'
Ordinary Shares (1,602,185 ADSs) exercisable at April 30, 2010 be exercised, Trinity Biotech
would have to issue 6,408,742 additional Class 'A' Ordinary Share
s
(1,602,185 ADSs
)
. On the
basis of 83,016,585 Class 'A' Ordinary Shares outstanding at April 30, 2010, this would
effectively dilute the ownership interest of the existing shareholders by approximately 7%.
It could be difficult for US holders of ADSs to enforce any securities laws claims against Trinity
Biotech, its officers or directors in Irish Courts.
•
At present, no treaty exists between the United States and Ireland for the reciprocal
enforcement of foreign judgements. The laws of Ireland do however, as a general rule, provide
that the judgements of the courts of the United States have in Ireland the same validity as if
rendered by Irish Courts. Certain important requirements must be satisfied before the Irish
Courts will recognize the United States judgement. The originating court must have been a
court of competent jurisdiction, the judgement may not be recognized if it is based on public
policy, was obtained by fraud or its recognition would be contrary to Irish public policy. Any
judgement obtained in contravention of the rules of natural justice will not be enforced in
Ireland.
NOTE REGARDING FORWARD-LOOKING STATEMENTS
This prospectus (including documents incorporated in it by reference in this prospectus)
contain forward-looking statements which involve known and unknown risks and uncertainties. We
include this notice for the express purpose of permitting Trinity Biotech to avail itself of the
protections of the safe harbor provided by the Private Securities Litigation Reform Act of 1995 for
all such forward looking statements. Examples of forward-looking statements include: (1)
projections of capital expenditures, revenues, growth, prospects, financial resources and other
financial matters; (2) statements of our plans or objectives; and (3) statements using the words
"anticipate," "believe," "estimate," "expect," "may," "intent," "plan," "project,"
"understand," and other verbs suggesting uncertainty.
6
Table of Contents
Our ability to predict results of Trinity Biotech's operations or the effects of certain
events on Trinity Biotech's operating results is inherently uncertain. Therefore, we caution you to
consider carefully the matters described under the caption "Risk Factors" and certain other matters
discussed in this prospectus (including the documents incorporated by reference in this
prospectus), and other publicly available sources. Such risks and many other factors beyond the
control of Trinity Biotech's management could cause the actual results, performance or achievements
of Trinity Biotech to be materially different from any future results, performance or achievements
that may be expressed or implied by the forward-looking statements.
USE OF PROCEEDS
The proceeds from the sale of the securities offered pursuant to this prospectus are solely
for the account of the selling shareholders. We will not receive any of the proceeds from any sale
of securities by the selling shareholders.
SELLING SHAREHOLDERS
The following table sets forth, for the selling shareholders as of April 30, 2010, the number
of Class 'A' Ordinary Shares and Class 'B' Ordinary Shares beneficially owned by each selling
shareholder, and the number of shares that may be offered by each selling shareholder using this
prospectus and each shareholder's percentage ownership of our outstanding shares assuming the sale
of all of the shares offered hereby. We prepared this table based on the information supplied to us
by the selling shareholders. Beneficial ownership is calculated based upon requirements of the
Securities and Exchange Commission and is not necessarily indicative of beneficial ownership for
any other purpose. Generally, the table is based on 83,016,585 Class 'A' Ordinary Shares and
700,000 Class 'B' Ordinary Shares outstanding as of April 30, 2010. The Percentage After Offering
column assumes the exercise of options for 573,334 Class 'A' Ordinary Shares held by the Selling
Shareholders.
We do not know when or in what amounts the selling shareholders may offer shares for sale. The
selling shareholders may not sell all or any of the shares offered by this prospectus.
Consequently, we cannot estimate the number of the shares that will be held by the selling
shareholders after completion of the offering. However, for purposes of the table below, we have
assumed that, after completion of the offering, none of the shares covered by this prospectus as of
the date of this prospectus will be held by the selling shareholders.
7
Table of Contents
This prospectus may be amended or supplemented from time to time to add selling shareholders
to or delete the names of selling shareholders from the following list or to otherwise amend or
supplement the information in the table set forth below.
Number of
Number of
Number of
Number of
Class 'A'
Class
Class 'A'
Class 'B'
Class
Class' B'
Ordinary
'A'
Ordinary
Ordinary
'B'
Ordinary
Percentage
Shares
Ordinary
Shares
Shares
Ordinary
Shares
Total
Beneficially
Shares
Beneficially
Beneficially
Shares
Beneficially
Voting
Owned
that may
Owned
Owned
that may
Owned
Power
Before
be
After
Before
be
After
After
Name
Offering
Offered
Offering
Offering
Offered
Offering
Offering
Rory Nealon
971,664
166,668
804,998
—
—
—
1.0
%
(1)
(41,667
(201,249
(242,916
ADS's)
ADS's)
ADS's)
Ronan O'Caoimh
5,308,330
266,666
5,041,664
—
—
—
6.0
%
(2)
(66,666
(1,260,416
(1,327,082
ADS's)
ADS's)
ADS's)
Peter Coyne
130,000
20,000
110,000
—
—
—
0.1
%
(3)
(5,000
(27,500
(32,500
ADS's)
ADS's)
ADS's)
Jim Walsh
1,657,362
20,000
1,637,362
—
—
—
1.9
%
(4)
(5,000
(409,340
(414,340
ADS's)
ADS's)
ADS's)
Denis Burger
270,000
20,000
250,000
—
—
—
0.3
%
(5)
(5,000
(62,500
(67,500
ADS's)
ADS's)
ADS's)
James Merselis
40,000
40,000
—
—
—
—
—
(6)
(10,000
(10,000
ADS's)
ADS's)
Clint Severson
88,000
40,000
48,000
—
—
—
0.1
%
(7)
(10,000
(12,000
(22,000
ADS's)
ADS's)
ADS's)
(1)
Includes 771,664 shares issuable upon exercise of options which are currently exercisable or
become exercisable within 60 days of the date of this prospectus.
(2)
Includes 1,470,834 shares issuable upon exercise of options which are currently exercisable or
become exercisable within 60 days of the date of this prospectus.
(3)
Includes 130,000 shares issuable upon exercise of options which are currently exercisable or
become exercisable within 60 days of the date of this prospectus.
(4)
Includes 263,750 shares issuable upon exercise of options which are currently exercisable or
become exercisable within 60 days of the date of this prospectus.
(5)
Includes 130,000 shares issuable upon exercise of options which are currently exercisable or
become exercisable within 60 days of the date of this prospectus.
(6)
Includes 40,000 shares issuable upon exercise of options which are currently exercisable or
become exercisable within 60 days of the date of this prospectus.
(7)
Includes 40,000 shares issuable upon exercise of options which are currently exercisable or
become exercisable within 60 days of the date of this prospectus.
8
Table of Contents
PLAN OF DISTRIBUTION
The Class 'A' Ordinary Shares covered by this prospectus may be offered and sold from time to
time by the selling shareholders. The term "selling shareholders" includes pledgees, donees,
transferees or other successors-in-interest selling shares received after the date of this
prospectus from the selling shareholders as a pledge, gift or other non-sale related transfer. To
the extent required, we may amend and supplement this prospectus from time to time to describe a
specific plan of distribution.
The selling shareholders will act independently of us in making decisions with respect to the
timing, manner and size of each sale. The selling shareholders may make these sales at prices and
under terms then prevailing or at prices related to the then current market price. The selling
shareholders may also make sales in negotiated transactions, including pursuant to one or more of
the following methods:
•
purchases by a broker-dealer as principal and resale by such broker-dealer for its own
account pursuant to this prospectus;
•
ordinary brokerage transactions and transactions in which the broker solicits purchasers;
•
one or more block trades in which the broker-dealer will attempt to sell the shares as
agent but may position and resell a portion of the block as principal to facilitate the
transaction;
•
an over-the-counter distribution in accordance with the rules of The Nasdaq Stock Market;
•
through brokers pursuant to pre-arranged sales plans intended to qualify under Rule l0b5-1
of the Securities Exchange Act of 1934, as amended (the "Exchange Act");
•
in privately negotiated transactions;
•
in any combination of one or more of these methods; and
•
in any other lawful method.
9
Table of Contents
In connection with distributions of the Class 'A' Ordinary Shares or otherwise, the selling
shareholders may:
•
enter into hedging transactions with broker-dealers or other financial institutions, which
may in turn engage in short sales of the shares in the course of hedging the positions they
assume;
•
sell the shares short and redeliver the shares to close out such short positions;
•
enter into option or other transactions with broker-dealers or other financial institutions
that require the delivery to them of shares offered by this prospectus, which they may in turn
resell; and
•
pledge shares to a broker-dealer or other financial institution, which, upon a default,
they may in turn resell.
In addition, the selling shareholders may sell all or a portion of the Class 'A' Ordinary
Shares that qualify for sale pursuant to Rule 144 or 145 under the Securities Act of 1933 (the
"Securities Act") rather than pursuant to this prospectus.
Sales through brokers may be made by any method of trading authorized by any stock exchange or
market on which the shares may be listed or quoted, including block trading in negotiated
transactions.
Without limiting the foregoing, such brokers may act as dealers by purchasing any or all of
the Class 'A' Ordinary Shares covered by this prospectus, either as agents for others or as
principals for their own accounts, and reselling such shares pursuant to this prospectus. The
selling shareholders may effect such transactions directly, or indirectly through underwriters,
broker-dealers or agents acting on their behalf. In effecting sales, broker-dealers or agents
engaged by the selling shareholder may arrange for other broker-dealers to participate.
Broker-dealers or agents may receive commissions, discounts or concessions from the selling
shareholders, in amounts to be negotiated immediately prior to the sale.
In offering the Class 'A' Ordinary Shares covered by this prospectus, the selling
shareholders, and any broker-dealers and any other participating broker-dealers who execute sales
for the selling shareholders, may be deemed to be "underwriters" within the meaning of the
Securities Act in connection with these sales. Any profits realized by the selling shareholders and
the compensation of such broker-dealers may be deemed to be underwriting discounts and commissions.
In order to comply with the securities laws of certain states, the Class 'A' Ordinary Shares
must be sold in those states only through registered or licensed brokers or dealers. In addition,
in certain states the shares may not be sold unless they have been registered or qualified for sale
in the applicable state or an exemption from the registration or qualification requirement is
available and is complied with.
We have advised the selling shareholders that the anti-manipulation rules of Regulation M
under the Exchange Act may apply to sales of Class 'A' Ordinary shares in the market and to the
activities of the selling shareholders and their respective affiliates. In addition, we will make
copies of this prospectus available to the selling shareholders for the purpose of satisfying the
prospectus delivery requirements of the Securities Act. The selling shareholders may indemnify
any broker-dealer that participates in transactions involving the sale of the shares against
certain liabilities, including liabilities arising under the Securities Act.
10
Table of Contents
All costs, expenses and fees in connection with the registration of the shares offered hereby
will be borne by us. Brokerage commissions and similar selling expenses, if any, attributable to
the sale of shares will be borne by the selling shareholders.
LIMITATION OF LIABILITY AND INDEMNIFICATION MATTERS
Our Articles of Association provide that every Director, Managing Director, agent secretary or
other officer of Trinity Biotech shall be entitled to be indemnified out of the assets of Trinity
Biotech against all losses or liabilities which he may sustain or incur in or about the execution
of the duties of his office or otherwise in relation thereto, including any liability incurred by
him in defending any proceeding, whether civil or criminal, in which judgment is given in his favor
or in which he is acquitted, and no Director or other officer shall be liable for any loss, damage
or misfortune which may happen to or be incurred by Trinity Biotech in the execution of the duties
of his office or in relation thereto.
Insofar as indemnification for liabilities arising under the Securities Act may be permitted
to directors, officers or persons controlling the registrant pursuant to the foregoing provisions,
the registrant has been informed that in the opinion of the Securities and Exchange Commission such
indemnification is against public policy as expressed in the Act and is therefore unenforceable.
11
Table of Contents
LEGAL MATTERS
The validity of the Class 'A' Ordinary Shares offered by this prospectus has been passed upon
for us by William Fry, Dublin, Ireland.
EXPERTS
The consolidated financial statements as of 31 December 2009 and 31 December 2008 and for each
of the years in the two year period ended 31 December 2009 incorporated in this prospectus by
reference from Trinity Biotech's Annual Report on Form 20-F for the year ended December 31, 2009 as
well as the effectiveness of internal control over financial reporting as of December 31, 2009 have
been audited by Grant Thornton, an independent registered public accounting firm, as stated in its
reports, which are incorporated herein by reference.
The consolidated statements of operations, recognized income and expenses and cash flows of
Trinity Biotech plc and subsidiaries for the year ended December 31, 2007 have been incorporated by
reference herein and in the registration statement in reliance upon the report of KPMG, an
independent registered public accounting firm, from Trinity Biotech's Annual Report on Form 20-F
for the year ended December 31, 2009, and upon the authority of said firms as experts in accounting
and auditing.
WHERE YOU CAN FIND MORE INFORMATION
We file annual and special reports and other information with the SEC. You may obtain these
filings over the internet at the SEC's web site at http://www.sec.gov. You may also read and copy
these filings at the SEC's public reference room at 450 Fifth Street, N.W., Washington, D.C. 20549.
You may obtain information on the operation of the public reference room by calling the SEC at
1-800-SEC-0330, and may obtain copies of Trinity Biotech's filings from the public reference room
by calling (202) 942-8090. Our internet address is http://www.trinitybiotech.com.
Trinity Biotech is a "foreign private issuer" as defined in Rule 3b-4 under the Exchange Act.
As a result, our proxy solicitations are not subject to the disclosure and procedural requirements
of Regulation 14A under the Exchange Act and transactions in Trinity Biotech's equity securities by
its officers and directors are exempt from Section 16 of the Exchange Act. In addition, Trinity
Biotech is not required under the Exchange Act to file periodic reports and financial statements as
frequently or as promptly as U.S. companies whose securities are registered under the Exchange Act.
Our ADSs are listed for quotation on the Nasdaq National Cap Market, and reports and other
information filed by us can be inspected at the offices of Nasdaq. Each ADS represents four Class A
Ordinary Shares of Trinity Biotech.
12
Table of Contents
INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE
The Securities and Exchange Commission regulations allow us to "incorporate by reference"
information into this prospectus, which means that we can disclose important information to you by
referring you to another document filed separately with the Securities and Exchange Commission. The
information incorporated by reference is considered part of this prospectus. Information
incorporated by reference from earlier documents is superseded by information set forth herein and
information that has been incorporated by reference from more recent documents.
The following documents filed by us with the Securities and Exchange Commission are
incorporated in this prospectus by reference:
(a) The Company's Annual Report on Form 20-F for the year ended December 31, 2009 filed on
April 15, 2010.
(b) All other reports filed by the Company with the Commission pursuant to Sections 13(a) or
15(d) of the 1934 Act, since December 31, 2009.
(c) A description of the ADSs and the Class 'A' Ordinary Shares is contained in Amendment No.
5 to the Company's Registration Statement on Form F-1 (File No. 333-48556) and in Item 10 in the
Company's
In addition, all documents subsequently filed by the Company pursuant to Section 13(a), 13(c),
14 or 15(d) of the Exchange Act, prior to the filing of a post-effective amendment to the
Registration Statement to which this prospectus pertains which indicates that all securities
offered hereby have been sold, or which deregisters all such securities then remaining unsold,
shall be deemed to be incorporated by reference in and made a part of the Registration Statement to
which this prospectus pertains from the date of filing of such documents.
Copies of any documents that are incorporated by reference herein, other than exhibits to such
documents, may be obtained upon request without charge by written or oral request from the
Company's Corporate Secretary, Trinity Biotech plc, IDA Business Park, Bray, Co. Wicklow, Ireland.
The Company's telephone number is +353 1 276 9800.
You should rely only on the information contained or incorporated by reference in this
prospectus. We have not authorized anyone to provide you with information that is different from
what is contained in this prospectus. This prospectus is dated May 6, 2010. You should not assume
that the information contained in this prospectus is accurate as of any date other than that date.
13
Table of Contents
573,334 CLASS 'A' ORDINARY SHARES
(143,333 ADS Equivalent)
TRINITY BIOTECH PLC
Class 'A' Ordinary Shares
PROSPECTUS
May 6, 2010
Table of Contents
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 3. Incorporation of Documents by Reference
The following documents which have been filed by the Company (File No. 0-22320) with the
Securities and Exchange Commission (the "Commission"), pursuant to the Securities Exchange Act of
1934, as amended (the "1934 Act") are incorporated by reference herein and shall be deemed to be a
part hereof.
(a) The Company's Annual Report on Form 20-F for the year ended December 31, 2009 filed on
April 15, 2010.
(b) All other reports filed by the Company with the Commission pursuant to Sections 13(a) or
15(d) of the 1934 Act, since December 31, 2009.
(c) A description of the ADSs and the Class 'A' Ordinary Shares is contained in Amendment No.
5 to the Company's Registration Statement on Form F-1 (File No. 333-48556) and in Item 10 in the
Company's Annual Report on Form 20-F for the fiscal year ended December 31, 2008.
In addition, all documents subsequently filed by the Company pursuant to Section 13(a), 13(c),
14 or 15(d) of the Exchange Act, prior to the filing of a post-effective amendment to this
Registration Statement which indicates that all securities offered hereby have been sold, or which
deregisters all such securities then remaining unsold, shall be deemed to be incorporated by
reference in and made a part of this Registration Statement from the date of filing of such
documents. Any statement contained in a document incorporated by reference shall be deemed to be
modified or superceded for purposes of this Registration Statement to the extent that it conflicts
with a statement contained herein or in any other subsequently filed document which also is or is
deemed to be incorporated by reference, and such statement shall not be deemed, except so modified
or superceded, to constitute a part of this Registration Statement.
Copies of any documents that are incorporated by reference herein, other than exhibits to such
documents, may be obtained upon request without charge by written or oral request from the
Company's Corporate Secretary, Trinity Biotech plc, IDA Business Park, Bray, Co. Wicklow, Ireland.
The Company's telephone number is 011 353 1 276 9800.
Item 4. Description of Securities
Not applicable.
Item 5. Interests of Named Experts and Counsel
Not applicable.
II-1
Table of Contents
Item 6. Indemnification of Directors and Officers
The Company's Articles of Association provide that every Director, Managing Director, agent
secretary or other officer of the Company shall be entitled to be indemnified out of the assets of
the Company against all losses or liabilities which he may sustain or incur in or about the
execution of the duties of his office or otherwise in relation thereto, including any liability
incurred by him in defending any proceeding, whether civil or criminal, in which judgment is given
in his favor or in which he is acquitted, and no Director or other officer shall be liable for any
loss, damage or misfortune which may happen to or be incurred by the Company in the execution of
the duties of his office or in relation thereto.
Item 7. Exemption from Registration Claimed — Not applicable.
Item 8. Exhibits
4.
Employee Share Option Plan 2006
5.
Opinion of William Fry
23.1
Consent of Grant Thornton, Independent Registered Public Accounting Firm
23.2
Consent of KPMG, Independent Registered Public Accounting Firm
23.3
Consent of William Fry (included in Exhibit 5)
24
Powers of Attorney (included in signature pages)
Item 9. Undertakings
(A) The undersigned registrant hereby undertakes:
(1) To file, during any period in which offers or sales are being made, a
post-effective amendment to this registration statement:
(i) To include any prospectus required by Section 10(a)(3) of the Securities Act of
1933;
(ii) To reflect in the prospectus any facts or events arising after the effective date
of the registration statement (or the most recent post-effective amendment thereof) which,
individually or in the aggregate, represent a fundamental change in the information set
forth in the registration statement. Notwithstanding the foregoing, any increase or decrease
in volume of securities offered (if the total dollar value of securities offered would not
exceed that which was registered) and any deviation from the low or high end of the
estimated maximum offering range may be reflected in the form of prospectus filed with the
Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price
represent no more than a 20 percent change in the maximum approximate
offering price set forth in the Calculation of Registration Fee table in the effective
registration statement.
II-2
Table of Contents
(iii) To include any material information with respect to the plan of distribution not
previously disclosed in the registration statement or any material change to such
information in the registration statement;
Provided, however,
that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information
required to be included in a post-effective amendment by those paragraphs is contained in periodic
reports filed with or furnished to the Commission by the registrant pursuant to section 13 or
section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the
registration statement.
(2) That, for the purpose of determining any liability under the Securities Act of
1933, each such post-effective amendment shall be deemed to be a new registration statement
relating to the securities offered therein, and the offering of such securities at that time
shall be deemed to be the initial
bona fide
offering thereof
(3) To remove from registration by means of a post-effective amendment any of the
securities being registered which remain unsold at the termination of the offering.
(B) The undersigned registrant hereby undertakes that, for the purposes of determining any
liability under the Securities Act of 1933, each filing of the registrant's annual report pursuant
to section 13(a) or section 15(d) of the Securities Exchange Act of 1934 (and, where applicable,
each filing of an employee benefit plan's annual report pursuant to section 15(d) of the Securities
Exchange Act of 1934) that is incorporated by reference in the registration statement shall be
deemed to be a new registration statement relating to the securities offered therein, and the
offering of such securities at that time shall be deemed to be the initial bona fide offering
thereof
(C) Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be
permitted to directors, officers and controlling persons of the Registrant pursuant to the
foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the
Securities and Exchange Commission such indemnification is against public policy as expressed in
the Act and is, therefore, unenforceable. In the event that a claim for indemnification against
such liabilities (other than the payment by the registrant of expenses incurred or paid by a
director, officer or controlling person of the registrant in the successful defense of any action,
suit or proceeding) is asserted by such director, officer or controlling person in connection with
the securities being registered, the registrant will, unless in the opinion of its counsel the
matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the
question whether such indemnification by it is against public policy as expressed in the Act and
will be governed by the final adjudication of such issue.
II-3
Table of Contents
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it
has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and
has duly caused this Registration Statement to be signed on its behalf by the undersigned,
thereunto duly authorized, in Dublin, Ireland on the 6
th
day of May, 2010.
TRINITY BIOTECH PLC
By:
/s/ Kevin Tansley
Kevin Tansley
Chief Financial Officer
II-4
Table of Contents
POWER OF ATTORNEY
Each person whose signature appears below hereby constitutes Kevin Tansley his true and lawful
attorney-in-fact with full power to execute in the name of such person, in the capacities stated
below, and to file, such one or more amendments to this Registration Statement as the Registrant
deems appropriate, and generally to do all such things in the name and on behalf of such person, in
the capacities stated below, to enable the Registrant to comply with the provisions of the
Securities Act of 1933, as amended, and all requirements of the Securities and Exchange Commission
thereunder, and hereby ratifies and confirms the signature of such person as it may be signed by
such attorney-in-fact to any and all amendments to this Registration Statement.
Pursuant to the requirements of the Securities Act of 1933, this Registration Statement and
the above power of attorney have been signed below by the following persons in the capacities
indicated on May 6, 2010.
Signature
Title
/s/ Ronan O'Caoimh
Ronan O'Caoimh
Chief Executive Officer
(Principal Executive Officer and Director)
/s/ Denis Burger
Denis Burger
Non-executive Director
(Authorized U.S. representative)
/s/ Rory Nealon
Rory Nealon
Chief Operations Officer and Director
/s/ Kevin Tansley
Kevin Tansley
Chief Financial Officer and Company Secretary
Non-executive Director
Peter Coyne
Non-executive Director
James D. Merselis
Non-executive Director
Clint Severson
/s/ James Walsh
James Walsh
Non-executive Director
II-5
Table of Contents
INDEX OF EXHIBITS
4.
Employee Share Option Plan 2006*
5.
Opinion of William Fry
23.1
Consent of Grant Thornton, Independent Registered Public Accounting Firm
23.2
Consent of KPMG, Independent Registered Public Accounting Firm
23.3
Consent of William Fry (included in Exhibit 5)
24
Powers of Attorney (included in signature pages)
*
Incorporated by reference to Exhibit 4 of the
registrant's annual report on Form 20-F for the year ended December 31, 2009.
II-6